Literature DB >> 24553551

Continuous glucose monitoring in the surgical intensive care unit: concordance with capillary glucose.

Kevin M Schuster1, Kimberly Barre, Silvio E Inzucchi, Robert Udelsman, Kimberly A Davis.   

Abstract

BACKGROUND: The role of intensive glycemic control (IGC) in the surgical intensive care unit (SICU) remains controversial. Continuous glucose monitoring systems (CGMSs) may mitigate the major risk of IGC, namely hypoglycemia, and improve clinical outcomes.
METHODS: All patients admitted to the SICU requiring insulin infusion were eligible. CGMS (Medtronic Guardian REAL-Time CGM, Northridge, CA) was placed in the subcutaneous tissue of the abdomen or thigh and calibrated every 8 hours, based on capillary (fingerstick) blood glucose (CBG) readings. Monitors were changed every 72 hours until 144 hours of observation was complete or insulin infusion stopped. CGM data were compared with CBG at least every 2 hours. Other data collected included demographics, diagnoses, fluid balance, doses of vasopressors and/or steroids, and any intravenous or enteral glucose source. CGMS and CBG readings were compared (mean and median absolute difference, correlation coefficients, Bland-Altman plots, and Clarke error grids).
RESULTS: Twenty-four patients were enrolled (11 men; mean [SD] age, 59 [14.1] years; mean [SD] body mass index 37.9 [10.1] kg/m; mean [SD] fluid resuscitation in the first 24 hours, 6.1 [3.5] L; 17 requiring vasopressor therapy). Correlation coefficient between CGMS and CBG was 0.61 (p < 0.001). The mean (SD) absolute difference was 22.0 [21.9] mg/dL and the median absolute difference was 16.0 mg/dL (interquartile rage, 7-31 mg/dL). The Bland-Altman plot did not identify any trends in accuracy. Clarke error grid analysis demonstrated that 98.92% of data points were in Zone A (71.30%), indicating agreement with CBG ± 20%, or Zone B (27.62%) (divergent but discrepancy would likely not lead to patient harm). Just 0.81% of data points were in Zone C (potentially dangerous overcorrection likely), and only 0.27% were in Zones D or E (potentially dangerous failure to detect hypoglycemia/hyperglycemia).
CONCLUSION: CGMS seems reasonably accurate in the SICU, despite widespread use of pressors and large-volume resuscitation. Further investigation into the accuracy and precision of these devices to assist clinicians in achieving IGC is warranted. LEVEL OF EVIDENCE: Diagnostic study, level III.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553551     DOI: 10.1097/TA.0000000000000127

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  10 in total

1.  Safety of using real-time sensor glucose values for treatment decisions in adolescents with poorly controlled type 1 diabetes mellitus: a pilot study.

Authors:  Larry A Fox; Emilie Balkman; Kim Englert; Jobayer Hossain; Nelly Mauras
Journal:  Pediatr Diabetes       Date:  2016-07-20       Impact factor: 4.866

2.  Accuracy of Continuous Glucose Monitoring in Patients After Total Pancreatectomy with Islet Autotransplantation.

Authors:  Gregory P Forlenza; Brandon M Nathan; Antoinette Moran; Ty B Dunn; Gregory J Beilman; Timothy L Pruett; Boris P Kovatchev; Melena D Bellin
Journal:  Diabetes Technol Ther       Date:  2016-04-22       Impact factor: 6.118

3.  Continuous Glucose Monitor Use and Accuracy in Hospitalized Patients.

Authors:  Vikash Dadlani; Yogish C Kudva
Journal:  Diabetes Technol Ther       Date:  2016-08-08       Impact factor: 6.118

4.  Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study.

Authors:  Eun Yeong Ha; Seung Min Chung; Il Rae Park; Yin Young Lee; Eun Young Choi; Jun Sung Moon
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

5.  Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline.

Authors:  Rodolfo J Galindo; Guillermo E Umpierrez; Robert J Rushakoff; Ananda Basu; Suzanne Lohnes; James H Nichols; Elias K Spanakis; Juan Espinoza; Nadine E Palermo; Dessa Garnett Awadjie; Leigh Bak; Bruce Buckingham; Curtiss B Cook; Guido Freckmann; Lutz Heinemann; Roman Hovorka; Nestoras Mathioudakis; Tonya Newman; David N O'Neal; Michaela Rickert; David B Sacks; Jane Jeffrie Seley; Amisha Wallia; Trisha Shang; Jennifer Y Zhang; Julia Han; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2020-09-28

6.  Continuous Glucose Monitoring Measures Can Be Used for Glycemic Control in the ICU: An In-Silico Study.

Authors:  Tony Zhou; Jennifer L Dickson; Geoffrey M Shaw; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2017-11-06

7.  Point accuracy and reliability of an interstitial continuous glucose-monitoring device in critically ill patients: a prospective study.

Authors:  Roosmarijn T M van Hooijdonk; Jan Hendrik Leopold; Tineke Winters; Jan M Binnekade; Nicole P Juffermans; Janneke Horn; Johan C Fischer; Edmée C van Dongen-Lases; Marcus J Schultz
Journal:  Crit Care       Date:  2015-02-05       Impact factor: 9.097

8.  Accuracy and Stability of a Subcutaneous Flash Glucose Monitoring System in Critically Ill Patients.

Authors:  Hiromu Naraba; Tadahiro Goto; Mitsuhiro Tokuda; Tomohiro Sonoo; Hidehiko Nakano; Yuji Takahashi; Hideki Hashimoto; Kensuke Nakamura
Journal:  J Diabetes Sci Technol       Date:  2021-06-11

Review 9.  Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.

Authors:  Awadhesh Kumar Singh; Ritesh Gupta; Amerta Ghosh; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2020-04-09

10.  Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19.

Authors:  Faruque Pathan; Shahjada Selim; Md Fariduddin; Md Hafizur Rahman; S M Ashrafuzzaman; Faria Afsana; Nazmul Kabir Qureshi; Tanjina Hossain; M Saifuddin; A B Kamrul-Hasan; Ahmed Salam Mir
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-18       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.